Abstract:Background Cancer vaccines are able to achieve tumor-specific immune editing in early-phase clinical trials. However, the infiltration of cytotoxic T cells into immune-deserted tumors is still a major limiting factor. An optimized vaccine approach to induce antigen-specific T cells that can perform robust tumor infiltration is important to accelerate their clinical translation. We previously developed a STING-activating PC7A nanovaccine that produces a strong anti-tumor T cell response on subcutaneous injection. This study systematically investigated the impact of administration methods on the performance of nanovaccines. Methods Tumor growth inhibition by intratumoral delivery and subcutaneous delivery of nanovaccine was investigated in TC-1 human papillomavirus-induced cancer model and B16-OVA melanoma model. Nanovaccine distribution in vivo was detected by clinical camera imaging, systemic T cell activation and tumor infiltration were tested by in vivo cytotoxicity killing assay and flow cytometry. For mechanism analysis, T cell recruitment was investigated by in vivo migration blocking assay, multiplex chemokine array, flow cytometry, RT-qPCR, chemotaxis assay and gene knockout mice. Results Nanovaccine administration was found to alter T cell production and infiltration in tumors. Intratumoral delivery of nanovaccines displayed superior antitumor effects in multiple tumor models compared with subcutaneous delivery. Mechanistic investigation revealed that intratumoral administration of the nanovaccine significantly increased the infiltration of antigen-specific T cells in TC-1 tumors, despite the lower systemic levels of T cells compared with subcutaneous injection. The inhibition of tumor growth by nanovaccines is primarily dependent on CD8 + cytotoxic T cells. Nanovaccine accumulation in tumors upregulates CXCL9 expression in myeloid cells in a STING dependent manner, leading to increased recruitment of IFNγ-expressing CD8 + T cells from the periphery, and IFNγ reciprocally stimulates CXCL9 expression in myeloid cells, resulting in positive feedback between myeloid-CXCL9 and T cell-IFNγ to promote T cell recruitment. However, the STING agonist alone could not sustain this effect in the presence of a systemic deficiency in antigen-specific T cells. Conclusions Our results demonstrate that intratumoral administration of PC7A nanovaccine achieved stronger antitumor immunity and efficacy over subcutaneous injection. These data suggest intratumoral administration should be included in the therapeutic design in the clinical use of nanovaccine.

Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γδ T Cells

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

Nanovaccine Based on a Protein-Delivering Dendrimer for Effective Antigen Cross-Presentation and Cancer Immunotherapy

Exploiting Immunostimulatory Mechanisms of Immunogenic Cell Death to Develop Membrane-Encapsulated Nanoparticles As a Potent Tumor Vaccine.

Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity

A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumors via a full-cycle immunomodulation

Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Nanovaccine’s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy

A Nanovaccine Based on Adjuvant Peptide FK‐13 and l‐Phenylalanine Poly(ester amide) Enhances CD8+ T Cell‐Mediated Antitumor Immunity

A "trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice

Dual-responsive Nanovaccine for Cytosolic Delivery of Antigens to Boost Cellular Immune Responses and Cancer Immunotherapy

Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens

Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy

Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy

Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane.

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

A Personalized Vaccine Combining Immunogenic Cell Death-Induced Cells and Nanosized Antigens for Enhanced Antitumor Immunity

Robust Anti‐Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy

Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy